BioXcel Therapeutics initiated with a Buy at Rodman & Renshaw

Rodman & Renshaw initiated coverage of BioXcel Therapeutics (BTAI) with a Buy rating and $65 price target The firm sees e blockbuster potential and over 2,900% share upside with BioXCel expanding the use of its approved drug, Igalmi, for at-home use and for Alzheimer’s disease. The convenience of using the drug at home grows the potential by tenfold, with a market potential of $2B in the U.S., the firm tells investors in a research note.